抗癌药物药物化学第二版 1849条(本栏目收费,不能显示细节,电话15274084725)
2.3. Gene-Directed Enzyme Prodrug Therapy and Virus-Directed Enzyme Prodrug Therapy .. 610 610
2.4. Antibody-Directed Enzyme Prodrug Therapy ... 613 613
3. Therapeutic Nanoparticles for Drug Delivery in Cancer: General Aspects ...617 617
4. Polymer Conjugates: Macromolecular Small-Drug Carrier Systems ..617 617
4.1. PEGylated Conjugates .... 619 619
4.2. N-(2-Hydroxypropyl)Methacrylamide Polymers .... 620 620
4.3. Poly-(L-Glutamic) Conjugates .... 625 625
4.4. Conjugates with Semisynthetic Hydrophilic Polyals ... 626 626
4.5. Neuropeptide Y Conjugates ..... 628 628
4.6. Antibody–Drug Conjugates .... 629 629
5. Polymer-Directed Enzyme Prodrug Therapy Approaches ....634 634
6. Folate Receptor-Targeted Chemotherapy ....635 635
7. Liposomes and Other Nanoparticles in Anticancer Drug Targeting ...640 640
7.1. Liposomes ..... 641 641
7.2. Copolymer Micelles .... 645 645
7.3. Gold Nanoparticles .... 648 648
7.4. Dendrimers as Carriers for the Delivery of Chemotherapeutic Agents .. 649 649
7.5. Nanoparticle Albumin-Bound Technology ... 649 649
References .......650 650
DRUGS THAT MODULATE RESISTANCE TO ANTITUMOR AGENTS...656 656
1. Introduction .....656 656
2. ABC efflux pumps in anticancer drug resistance ...657 657
2.1. General features of ABC efflux pumps ... 657 657
2.2. Inhibition of P-glycoprotein .... 659 659
2.3. Indirect inhibitors of MDR .... 668 668
2.4. Importance of the Pgp inhibition data in new drug applications ... 668 668
3. Glutathione and glutathione S-transferase in anticancer drug resistance ...668 668
3.1. Inhibitors of glutathione biosynthesis .... 669 669
3.2. Inhibitors of glutathione S-transferase ... 671 671
3.2.1. Role of glutathione S-transferase in anticancer drug resistance .. 671 671